Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
/in Breast Cancer, Dendritic Cells, Hypernephroma, International Publications /von 2011-10-20 / J Transl Med 2011 Oct;9:178Proving the principle: dendritic cell-based vaccines in urogenital cancers
/in Dendritic Cells, Hypernephroma, International Publications, Prostate Cancer /von 2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis
/in Dendritic Cells, Hypernephroma, International Publications, Prostate Cancer /von 2011-04-20 / PLoS ONE 2011 Apr;6(4):e18801Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2010-10-22 / BMC Cancer 2010 Oct;10:578Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2
/in Dendritic Cells, Hypernephroma, International Publications /von 2010-05-01 / J. Immunother. 2010 May;33(4):425-34Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate
/in Hypernephroma, International Publications /von 2009-11-01 / Scand. J. Immunol. 2009 Nov;70(5):481-9Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81Vaccination strategies in patients with renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-74Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses
/in Hypernephroma, International Publications /von 2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-97
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de